

IN THE MATTER OF \* BEFORE THE MARYLAND  
ALISHA GRINDER, \* STATE BOARD OF  
PHARMACY TECHNICIAN \* PHARMACY  
Registration No.: T05132 \* Case No.: 21-184

\* \* \* \* \*

**ORDER FOR SUMMARY SUSPENSION**

The Maryland Board of Pharmacy (the "Board") hereby summarily suspends the registration to practice as a Pharmacy Technician ("Pharm Tech") in Maryland issued to **Alisha Grinder** (the "Respondent"), under the Maryland Pharmacy Act (the "Act"), Md. Code Ann., Health Occupations ("Health Occ"), §§ 12-101 *et seq.* (2014 Repl. Vol. and 2020 Supp.), registration number T05132. The Board takes such action pursuant to Md. Code Ann., State Gov't §§ 10-226(c)(2) (2014 Repl. Vol. and 2020 Supp.), concluding that the public health, safety or welfare imperatively requires emergency action.

This Order is based on the following investigative findings, which the Board has reason to believe are true:

**INVESTIGATIVE FINDINGS**<sup>1</sup>

1. At all times relevant hereto, the Respondent practiced as a Pharm Tech in the State of Maryland. The Respondent was first registered as a Pharm Tech in Maryland on or about April 17, 2009. The Respondent's registration is scheduled to expire on August 31, 2022.

**Complaint**

---

<sup>1</sup> The statements regarding the Respondent's conduct are only intended to provide the Respondent with notice of the basis for the Board's action. They are not intended as, and do not necessarily represent, a complete description of the evidence, either documentary or testimonial, to be offered against the Respondent in this matter.

2. On or about February 17, 2021, the Board received a Drug Enforcement Administration (DEA) Form 106, *Report of Theft or Loss of Controlled Substances* (the “Complaint”) from a national chain Pharmacy located in Aberdeen, Maryland (the “Pharmacy”).<sup>2</sup>
3. The form states that on or about January 6, 2021, the loss of the controlled dangerous substances (CDS) was identified because of a suspected or actual employee theft due to employee theft, specifically as follows:

<u>Medication &amp; Dosage</u>	<u>Quantity</u>
Clonazepam 0.5mg	114
Hydrocodone-Acetaminophen 5-325mg	261
Hydrocodone-Acetaminophen 7.5-325mg	63
Oxycodone-Acetaminophen 5-325mg	181
Oxycodone HCL 5mg	37
Pentermine 37.5mg	44
Hydrocodone-Acetaminophen 7.5-325mg	1
Pentermine 37.5mg	315
Pentermine 37.5mg	21
Oxycodone HCL 10mg	23

<sup>2</sup> For confidentiality and privacy purposes, the names of individuals and facilities involved in this case are not disclosed in this document. Upon written request, the Administrative Prosecutor will provide the information to the Respondent.

Clonazepam 1mg	222
Clonazepam 0.5mg	27
Tramadol HCL 50mg	181
Dextroamp-Amphet ER (“Adderall”) 25mg	1
Tramadol HCL 50mg	236
Tramadol HCL 50mg	155

4. Based on the Complaint, the Board initiated an investigation.

**Investigation**

5. Subsequently, on March 12 and March 18, 2021, pursuant to a subpoena, the Board obtained additional documentation from the Pharmacy regarding the Pharmacy’s internal investigation into the theft.
6. The documentation indicated that on or about December 29, 2020, the Pharmacy’s manager reported to the Pharmacy’s Protection Management that the Respondent, who was employed there as a Pharm Tech, had diverted several tablets of Adderall and Oxycodone. Based on the manager’s report, the Pharmacy initiated an investigation that included reviewing in-store security video and inventory data, and interviewing the Respondent. The investigation identified further instances of the Respondent diverting CDS without authorization.

7. The documentation obtained by the Board included a January 6, 2021 voluntary written statement by the Respondent admitting that she stole CDS “on several occasions,” including: clonazepam, tramadol, phentermine, oxycodone, and Adderall. In the statement, the Respondent cited stressful personal issues as the reason for her actions.
8. On or about January 6, 2021, the Respondent was terminated from the Pharmacy based on the theft.
9. Based on the information provided to the Board by the Pharmacy, the Board has reason to believe that the Respondent diverted multiple medications over an extended time span.

#### CONCLUSIONS OF LAW

Based on the foregoing investigative findings, the Board concludes as a matter of law that the public health, safety, and welfare imperatively require emergency action in this case, pursuant to Md. Code Ann., State Gov’t § 10-226(c)(2) (2014 Repl. Vol. and 2020 Supp.).

#### ORDER

Based on the foregoing Investigative Findings and Conclusions of Law, it is this 14<sup>th</sup> day of May 2021, by a majority of the quorum of the Board, hereby:

**ORDERED** that pursuant to the authority vested in the Board by Md. Code Ann., State Gov’t § 10-226(c)(2) (2014 Repl. Vol. and 2020 Supp.), the Respondent’s

registration to practice as a Pharmacy Technician in the State of Maryland under registration number T05132 is hereby **SUMMARILY SUSPENDED**; and it is further

**ORDERED** that the Respondent is prohibited from practicing as a Pharmacy Technician in the State of Maryland; and it is further


**ORDERED** that the Respondent shall immediately return all copies of his registration to the Board; and it is further

**ORDERED** that the Respondent has the opportunity to appear before the Board for a post-deprivation show cause hearing. A request for a post-deprivation show cause hearing must be in writing and be made **WITHIN THIRTY (30) DAYS**; and it is further

**ORDERED** that if the Respondent fails to request a post-deprivation show cause hearing in writing in a timely manner, or if the Respondent requests a post-deprivation show cause hearing but fails to appear when scheduled, the Respondent's registration will remain **SUSPENDED**; and it is further

**ORDERED** that this **ORDER FOR SUMMARY SUSPENSION** is a **PUBLIC DOCUMENT** pursuant to Md. Code Ann., Gen. Prov. §§ 4-101 *et seq.* (2014).

5-14-21  
Date

  
\_\_\_\_\_  
Deena Speights-Napata, M.A.,  
Executive Director  
*on behalf of*  
Jennifer L. Hardesty, Pharm.D.  
Board President